Table 1 Summary of primary antibodies used in this study.
From: Simultaneous deactivation of FAK and Src improves the pathology of hypertrophic scar
Target protein | Cat no. | Lot no. | Host | Vendor | Dilution | |||
|---|---|---|---|---|---|---|---|---|
IB | IHC | IF | IP | |||||
p-FAK-Tyr407 | 44650 G | 0400#8 A | Rabbit | Invitrogen | 1:1000 | 1:50 | 1:100 | |
FAK | sc-558 | E1513 | Rabbit | Santa cruz biotechnology | 1:200 | 1:50 | 1:100 | |
p-Src-Tyr529 | ab32078 | YH080908D | Rabbit | Abcam | 1:1000 | 1:50 | 1:100 | |
p-Src-Tyr416 | 6943 s | 1 | Rabbit | Cell signaling technology | 1:1000 | |||
Src | sc-8056 | F3011 | Mouse | Santa cruz biotechnology | 1:200 | 1:50 | 1:100 | 1:50 |
Col I | ab96723 | GR190879-1 | Rabbit | Abcam | 1:1000 | |||
Col III | ab7778 | NBP1-05119 | Rabbit | Abcam | 1:1000 | |||
α-SMA | ab7817 | 1184-1 | Rabbit | Abcam | 1:1000 | |||
Actin | sc-1616 | B2013 | Goat | Santa cruz biotechnology | 1:500 | |||
